menu
    • menu
    [{"orgOrder":0,"company":"AMOREPACIFIC CORPORATION","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Gamma-Aminobutyric Acid","moa":"GABR||Gamma-aminobutyric acid receptor subunit gamma-2; Sodium- and chloride-dependent GABA transporter 3; Integrin alpha-4; Gamma-aminobutyric acid receptor subunit alpha-2; Gamma-aminobutyric acid receptor subunit alpha-3; Gamma-aminobutyric acid receptor subunit beta-2; Gamma-aminobutyric acid receptor subunit alpha-1; Gamma-aminobutyric acid receptor subunit alpha-5; Sodium- and chloride-dependent GABA transporter 1; Gamma-aminobutyric acid type B receptor subunit 1; Gamma-aminobutyric acid type B receptor subunit 2; Glycine amidinotransferase, mitochondrial","graph1":"Sleep","graph2":"Undisclosed","graph3":"AMOREPACIFIC CORPORATION","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AMOREPACIFIC CORPORATION \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"AMOREPACIFIC CORPORATION \/ Undisclosed"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"Diamyd Medical AB | NOW Foods | Johnson & Johnson Innovative Medicine | Juvenile Diabetes Research Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Gamma-Aminobutyric Acid","moa":"GABR||Gamma-aminobutyric acid receptor subunit gamma-2; Sodium- and chloride-dependent GABA transporter 3; Integrin alpha-4; Gamma-aminobutyric acid receptor subunit alpha-2; Gamma-aminobutyric acid receptor subunit alpha-3; Gamma-aminobutyric acid receptor subunit beta-2; Gamma-aminobutyric acid receptor subunit alpha-1; Gamma-aminobutyric acid receptor subunit alpha-5; Sodium- and chloride-dependent GABA transporter 1; Gamma-aminobutyric acid type B receptor subunit 1; Gamma-aminobutyric acid type B receptor subunit 2; Glycine amidinotransferase, mitochondrial","graph1":"Endocrinology","graph2":"Phase I","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alabama at Birmingham \/ Diamyd Medical AB | NOW Foods | Johnson & Johnson Innovative Medicine | Juvenile Diabetes Research Foundation","highestDevelopmentStatusID":"6","companyTruncated":"University of Alabama at Birmingham \/ Diamyd Medical AB | NOW Foods | Johnson & Johnson Innovative Medicine | Juvenile Diabetes Research Foundation"},{"orgOrder":0,"company":"University of Florida","sponsor":"National Institute on Aging | Thorne HealthTech","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Gamma-Aminobutyric Acid","moa":"GABR||Gamma-aminobutyric acid receptor subunit gamma-2; Sodium- and chloride-dependent GABA transporter 3; Integrin alpha-4; Gamma-aminobutyric acid receptor subunit alpha-2; Gamma-aminobutyric acid receptor subunit alpha-3; Gamma-aminobutyric acid receptor subunit beta-2; Gamma-aminobutyric acid receptor subunit alpha-1; Gamma-aminobutyric acid receptor subunit alpha-5; Sodium- and chloride-dependent GABA transporter 1; Gamma-aminobutyric acid type B receptor subunit 1; Gamma-aminobutyric acid type B receptor subunit 2; Glycine amidinotransferase, mitochondrial","graph1":"Neurology","graph2":"Phase II","graph3":"University of Florida","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Florida \/ National Institute on Aging | Thorne HealthTech","highestDevelopmentStatusID":"8","companyTruncated":"University of Florida \/ National Institute on Aging | Thorne HealthTech"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Gamma-Aminobutyric Acid","moa":"||GABR","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Diamyd Medical AB \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Diamyd Medical AB \/ Undisclosed"},{"orgOrder":0,"company":"MDbio Wellness","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabis Sativa Oil","moa":"||Undisclosed","graph1":"Sleep","graph2":"Approved FDF","graph3":"MDbio Wellness","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MDbio Wellness \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"MDbio Wellness \/ Undisclosed"},{"orgOrder":0,"company":"TCI Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Gamma-Aminobutyric Acid","moa":"GABR","graph1":"Sleep","graph2":"Undisclosed","graph3":"TCI Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Liquid","sponsorNew":"TCI Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"TCI Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Per-Ola Carlsson","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Gamma-Aminobutyric Acid","moa":"GABR","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Diamyd Medical AB \/ Per-Ola Carlsson","highestDevelopmentStatusID":"7","companyTruncated":"Diamyd Medical AB \/ Per-Ola Carlsson"}]

    Find Clinical Drug Pipeline Developments & Deals for Gamma-Aminobutyric Acid

    Menu

    Gamma-Aminobutyric Acid

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            TCI Co., Ltd.

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            TCI Co., Ltd.

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gamma-Aminobutyric Acid

                            Therapeutic Area : Sleep

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Effect of Avnace eZZe on Sleep Improvement

                            Details : Gamma-Aminobutyric Acid is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Undisclosed clinical studies for the treatment of Sleep Wake Disorders.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 15, 2025

                            Lead Product(s) : Gamma-Aminobutyric Acid

                            Therapeutic Area : Sleep

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            MDbio Wellness

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            MDbio Wellness

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabis Sativa Oil,Gamma-Aminobutyric Acid,L-Theanine

                            Therapeutic Area : Sleep

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MDbio Starts Clinical Trials for Pharmaceutical-Grade Products That Target Sleeplessness, Stress and Pain

                            Details : MDsleep (cannabis sativa oil), also known as hemp seed oil, is a lightweight oil cold-pressed from the seeds of the Cannabis sativa plant. It’s been used for centuries in cooking, as well as topically to help with a wide range of skin concerns.

                            Product Name : MDsleep

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            July 22, 2022

                            Lead Product(s) : Cannabis Sativa Oil,Gamma-Aminobutyric Acid,L-Theanine

                            Therapeutic Area : Sleep

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AMOREPACIFIC CORPORATION

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            AMOREPACIFIC CORPORATION

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gamma-Aminobutyric Acid

                            Therapeutic Area : Sleep

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Study to Investigate the Sleep Quality Enhancing Effect of GABA

                            Details : GABA is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Sleep Wake Disorders.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 23, 2021

                            Lead Product(s) : Gamma-Aminobutyric Acid

                            Therapeutic Area : Sleep

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            University of Florida

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            University of Florida

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gamma-Aminobutyric Acid

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : National Institute on Aging | Thorne HealthTech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Latent Aging Mechanisms in Pain and Sleep

                            Details : GABA is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Chronic Pain.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 24, 2020

                            Lead Product(s) : Gamma-Aminobutyric Acid

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : National Institute on Aging | Thorne HealthTech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Diamyd Medical AB

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Diamyd Medical AB

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gamma-Aminobutyric Acid,Alprazolam

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Diamyd Medical Reports that Clinical Trial with Remygen[®] is Expanded to Evaluate Prevention of Hypoglycaemi...

                            Details : The Swedish Medical Products Agency has approved an amendment to ReGenerate-1 to investigate Remygen®'s preventive effects on hypoglycaemia (severely reduced blood sugar level) in individuals with long-term type 1 diabetes.

                            Product Name : Remygen

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 24, 2020

                            Lead Product(s) : Gamma-Aminobutyric Acid,Alprazolam

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Diamyd Medical AB

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Diamyd Medical AB

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gamma-Aminobutyric Acid

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Per-Ola Carlsson

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of Safety and Diabetes Status Upon Oral Treatment With GABA in Patients With Longstanding Type-1 Di...

                            Details : Gamma-Aminobutyric Acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Diabetes Mellitus, Type 1.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 17, 2018

                            Lead Product(s) : Gamma-Aminobutyric Acid

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Per-Ola Carlsson

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            University of Alabama at Birmingham

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            University of Alabama at Birmingham

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gamma-Aminobutyric Acid

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Diamyd Medical AB | NOW Foods | Johnson & Johnson Innovative Medicine | Juvenile Diabetes Research Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Use of Glutamic Acid Decarboxylase (GAD) and Gamma-Amino Butyric Acid (GABA) in the Treatment of Type I Di...

                            Details : GABA is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 1.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 05, 2013

                            Lead Product(s) : Gamma-Aminobutyric Acid

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Diamyd Medical AB | NOW Foods | Johnson & Johnson Innovative Medicine | Juvenile Diabetes Research Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth